ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,946.20
      0.26%
      US Tech 100
      20,784.00
      0.18%
      Dow Jones
      42,748.63
      -0.21%
      Brent Oil
      71.79
      -1.27%
      Bitcoin
      94,094.60
      -1.07%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Altimmune Inc (ALT) Quote

      Altimmune Inc

      Altimmune Inc (ALT)

      Analytica Limited
      Altitude Group Plc
      Alturas Minerals Corp
      7.8634
      -0.3866
      ( -4.69% )
      Updated: 11:40:04
      Delayed by 15 minutes

      Empower your portfolio: Real-time discussions and actionable trading ideas.

      Premium

      Key stats and details

      Current Price
      7.8634
      Bid
      7.86
      Ask
      7.87
      Volume
      920,685
      7.86 Day's Range 8.25
      5.275 52 Week Range 14.84
      Market Cap
      559.281M
      Previous Close
      8.25
      Open
      8.22
      Last Trade
      10
      @
      7.86
      Last Trade Time
      11:40:04
      Financial Volume
      $ 7,397,345
      VWAP
      8.0346
      Average Volume (3m)
      3,132,583
      Shares Outstanding
      71,124,625
      Dividend Yield
      -
      PE Ratio
      -6.36
      Earnings Per Share (EPS)
      -1.24
      Revenue
      426k
      Net Profit
      -88.45M

      About Altimmune Inc

      Altimmune Inc is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the tre... Altimmune Inc is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH (non-alcoholic steatohepatitis). In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B virus (HBV). Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.altimmune.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      Altimmune Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ALT. The last closing price for Altimmune was $8.25. Over the last year, Altimmune shares have traded in a share price range of $ 5.275 to $ 14.84.

      Altimmune currently has 71,124,625 shares outstanding. The market capitalization of Altimmune is $586.78 million. Altimmune has a price to earnings ratio (PE ratio) of -6.36.

      Ask ADVFN Intelligence (AI)

      Altimmune (ALT) Options Flow Summary

      ALT Options Flow

      Overall Flow

      Bullish

      Net Premium

      635k

      Calls / Puts

      100.00%

      Buys / Sells

      175.00%

      OTM / ITM

      1,000.00%

      Sweeps Ratio

      0.00%

      ALT Latest News

      More News

      Altimmune Added to Nasdaq Biotechnology Index

      GAITHERSBURG, Md., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will be added to the Nasdaq Biotechnology...

      December 19 2024
      GlobeNewswire Inc.

      Form 8-K - Current report

      December 11 2024
      Edgar (US Regulatory)

      Altimmune to Present at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders

      GAITHERSBURG, Md., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at...

      December 02 2024
      GlobeNewswire Inc.

      Altimmune to Participate at Two Upcoming Investor Conferences

      GAITHERSBURG, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Companyā€™s management team will...

      November 26 2024
      GlobeNewswire Inc.

      Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver MeetingĀ® 2024

      Weekly subcutaneous doses of pemvidutide resulted in robust reductions in cardio-inflammatory, hepato-inflammatory and atherosclerotic lipids Findings support the potential benefit of pemvidutide...

      November 15 2024
      GlobeNewswire Inc.

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]

      November 12 2024
      Edgar (US Regulatory)

      Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update

      Enrollment completed in Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH); top-line efficacy data expected in Q2 2025 Successful completion of the...

      November 12 2024
      GlobeNewswire Inc.

      Form 8-K - Current report

      November 12 2024
      Edgar (US Regulatory)

      Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      GAITHERSBURG, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Compensation Committee of its Board of...

      November 11 2024
      GlobeNewswire Inc.
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-1.1966-13.20750551889.069.597.704535924198.28212714CS
      4-1.0666-11.94400895868.9310.887.704534140118.89345006CS
      121.533424.2243285946.3311.165.8631325838.1333656CS
      260.41345.548993288597.4511.165.27530879217.47621705CS
      52-1.6766-17.57442348019.5414.845.27539681238.82873053CS
      156-1.3166-14.34204793039.1823.492.0929217528.12183992CS
      2606.1034346.7840909091.7635.11.625166049.70740848CS

      ALT - Frequently Asked Questions (FAQ)

      What is the current Altimmune share price?
      The current share price of Altimmune is $ 7.8634
      How many Altimmune shares are in issue?
      Altimmune has 71,124,625 shares in issue
      What is the market cap of Altimmune?
      The market capitalisation of Altimmune is USD 586.78M
      What is the 1 year trading range for Altimmune share price?
      Altimmune has traded in the range of $ 5.275 to $ 14.84 during the past year
      What is the PE ratio of Altimmune?
      The price to earnings ratio of Altimmune is -6.36
      What is the cash to sales ratio of Altimmune?
      The cash to sales ratio of Altimmune is 1.32k
      What is the reporting currency for Altimmune?
      Altimmune reports financial results in USD
      What is the latest annual turnover for Altimmune?
      The latest annual turnover of Altimmune is USD 426k
      What is the latest annual profit for Altimmune?
      The latest annual profit of Altimmune is USD -88.45M
      What is the registered address of Altimmune?
      The registered address for Altimmune is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
      What is the Altimmune website address?
      The website address for Altimmune is www.altimmune.com
      Which industry sector does Altimmune operate in?
      Altimmune operates in the PHARMACEUTICAL PREPARATIONS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      DRCTDirect Digital Holdings Inc
      $ 2.51
      (356.36%)
      		20.87M
      RELIReliance Global Group Inc
      $ 3.77
      (214.17%)
      		89.84M
      TRAWTraws Pharma Inc
      $ 13.8152
      (175.20%)
      		23.77M
      OCCOptical Cable Corporation
      $ 4.89
      (132.86%)
      		5.09M
      RAPTRAPT Therapeutics Inc
      $ 1.58
      (91.42%)
      		110.12M
      AILEiLearningEngines Inc
      $ 0.2638
      (-70.19%)
      		10.85M
      MGOLMGO Global Inc
      $ 0.4249
      (-55.27%)
      		8.21M
      TNXPTonix Pharmaceuticals Holding Corporation
      $ 0.4139
      (-32.33%)
      		107.37M
      YHCLQR House Inc
      $ 1.1848
      (-32.30%)
      		925.6k
      NVNINVNI Group Ltd
      $ 6.10
      (-28.90%)
      		2.39M
      EDBLEdible Garden AG Inc
      $ 0.4161
      (75.05%)
      		314.62M
      RGTIRigetti Computing Inc
      $ 11.1601
      (19.10%)
      		164.04M
      RAPTRAPT Therapeutics Inc
      $ 1.58
      (91.42%)
      		110.12M
      TNXPTonix Pharmaceuticals Holding Corporation
      $ 0.4139
      (-32.33%)
      		107.37M
      RELIReliance Global Group Inc
      $ 3.77
      (214.17%)
      		89.84M

      ALT Discussion

      View Posts
      Mark102 Mark102 3 weeks ago
      Still Holding here
      As far as buyout and the OS you're looking at roughly 7 billion = 100 a share
      10 billion = 140

      👍 1
      Mark102 Mark102 5 months ago
      As promised I don't see any dilution in the filing. Shorts are in trouble
      👍 1
      Mark102 Mark102 5 months ago
      Float is Locked and over 23 million naked shares Short. Shorts have failed Miserably at shaking out Retail and can't cover without a massive loss.
      Price Targets
      Partner 50 to 75
      Buyout 140 to 200
      👍 1
      Mark102 Mark102 5 months ago
      https://forextv.com/top-news/altimmune-announces-publication-of-clinical-study-of-pemvidutide-in-metabolic-dysfunction-associated-steatotic-liver-disease-masld-in-journal-of-hepatology/
      👍 1 💯 1
      Mark102 Mark102 5 months ago
      IT'S HAPPENING
      šŸ‘ļø0
      Mark102 Mark102 6 months ago
      Beautiful Bull Flag
      šŸ‘ļø0
      girlfriend girlfriend 6 months ago
      Well....not quite but a nice pop anyways this week.
      šŸ‘ļø0
      Mark102 Mark102 6 months ago
      Last chance next week above 20
      šŸ‘ļø0
      Mark102 Mark102 6 months ago
      It's being shorted by its competitors not tutes. . An advisor from Lilly is making the presentations of pemvi data this weekend.its what you know not what some want you to believe.
      👍 1
      brfv11 brfv11 6 months ago
      Not a chance at 60. Shorts are playing this one perfectly. Investors are just not interested in ALT. Good luck.
      👍 1
      Mark102 Mark102 6 months ago
      Shorts looking weak and vulnerable today any trading room with the funds could squeeze this to 60 easy
      šŸ‘ļø0
      Mark102 Mark102 6 months ago
      Goldman Sachs been short stacking here for months and they are hosting the fireside tomorrow. I'm loading up today
      šŸ‘ļø0
      brfv11 brfv11 7 months ago
      Time to admit shorty got this one right! This one is going all the way down.
      Merger/ buyout what a joke.
      šŸ‘ļø0
      akamaii akamaii 7 months ago
      This Wednesday we hope data rules. Give us data 📈
      šŸ‘ļø0
      akamaii akamaii 8 months ago
      Going long for a year 75 target or 50 plus
      šŸ‘ļø0
      Mt. Blanc Mt. Blanc 8 months ago
      So much for my ALT prediction.

      The stock slipped to $7 and may be cratering more since it's getting no love.

      Maybe ALT is a $5 stock or lower if buyers aren't interested.

      mb
      šŸ‘ļø0
      Mt. Blanc Mt. Blanc 9 months ago
      Radar. ALT $11- $12

      Getting picked up.

      mb
      šŸ‘ļø0
      Monksdream Monksdream 9 months ago
      ALT over $10
      Next day settlement begins 5/28 per SEC mandate
      šŸ‘ļø0
      Monksdream Monksdream 9 months ago
      ALT 10Q due 3/27
      Next day settlement begins 5/28
      šŸ‘ļø0
      saigai saigai 9 months ago
      patiently waiting.. for sure something in the way of news is right there and it can only be a plus.. i want the buyout.. let say 4 billion.. 80 bucks a share..gl
      šŸ‘ļø0
      Mark102 Mark102 9 months ago
      Buyout? Partnership? In less than 9 trading days we will find out.
      šŸ‘ļø0
      Mark102 Mark102 9 months ago
      BUCKLE UP. going to break 15 soon
      šŸ‘ļø0
      saigai saigai 10 months ago
      a good read
      https://www.rcplondon.ac.uk/news/world-obesity-day-let-s-talk-about-drugs
      šŸ‘ļø0
      saigai saigai 10 months ago
      slow and steady is healthy as the data goes as well.. fast weight loss is never good and the deeper dive into the data im sure will find that Alt has a wider profile a safer profile as it relates to muscle loss and bone density. time will tell...in any case the real value here is the undiscovered uses.. wide profile more mkts...long and strong ...
      šŸ‘ļø0
      Mt. Blanc Mt. Blanc 10 months ago
      ALT @ $12?

      Interesting

      mb
      šŸ‘ļø0
      saigai saigai 10 months ago
      institutional ownership from nasdaq site
      https://www.nasdaq.com/market-activity/stocks/alt/institutional-holdings
      šŸ‘ļø0
      saigai saigai 10 months ago
      big volume wrong direction for now
      šŸ‘ļø0
      saigai saigai 10 months ago
      a good read
      https://finance.yahoo.com/news/weight-loss-drugs-patients-lose-134837816.html
      šŸ‘ļø0
      saigai saigai 11 months ago
      and a few more...
      šŸ‘ļø0
      saigai saigai 11 months ago
      you wont be able to chase this..you either in before the news or outside looking in.. patience of a saint..
      šŸ‘ļø0
      saigai saigai 11 months ago
      driving me nutz but i wont sell this until !!!
      šŸ‘ļø0
      murocman murocman 11 months ago
      Post from another board relevant to ALT:

      GLP-1 drugs will_be supply-constrained for_a_few_years, according to the NVO and LLY webcasts at JPM. All in-house and CMO capacity suitable for manufacturing injected GLP-1 drugs is already in service. Moreover, the eventual uptake of oral GLP-1 drugs will not ease the manufacturing bottleneck as much as people might think because the low bioavailability of the oral agents requires large amounts of API.
      šŸ‘ļø0
      AGORDON AGORDON 11 months ago
      Altimmune, Inc.
      (Nasdaq - ALT) $12/share
      Market cap = $644M
      Cash = $140M
      Cash Burn rate = ($76)/Y
      Catalysts:
      Pemvidutide - Weight loss drug. Peptide based GLP-1/Glucagon dual receptor agonist. Phase 2 results were respectable. At 48 weeks, for 2.4mg (high dose), weight loss of -15.6% (on the low end of the expected 15-20%)., but comparable to Mounjaro. The TRAEs appear to be less than Mounjaro's. The drug did reduce triglycerides.
      HepTCell - an immunotherapeutic for Chronic Hepatitis B. In Phase 2 trials. Next read out could be in April, 2024.
      šŸ‘ļø0
      Mark102 Mark102 11 months ago
      I was wrong ALT is attending the JPM Let's get this deal done.
      šŸ‘ļø0
      saigai saigai 11 months ago
      thanks a lot.. im on a new computer.. id rather have oral surgery than learn a new computer
      šŸ‘ļø0
      Mark102 Mark102 12 months ago
      Data is in check Twitter. Weight loss is a 100 billion market. The results on the liver data show a 100 % reduction of fat at the highest dose. That's a 40 billion market.
      Now why is ALT not attending the JPM conference this week? Stay tuned
      šŸ‘ļø0
      saigai saigai 12 months ago
      im hanging around bewteen the two potential mkts for their drug its too crazy to even think out loud lets see what the data says.. if its good or really good. all hell will break out
      šŸ‘ļø0
      Mark102 Mark102 12 months ago
      Float is locked, tutes trying to shake few out but this is a done deal IMO
      šŸ‘ļø0
      saigai saigai 12 months ago
      this is a powder keg...
      šŸ‘ļø0
      saigai saigai 12 months ago
      i believe if they wanted to they could have closed a deal by now but they wait till after the new data.. i wonder why.. there is no way for this to go but way up from here..glta
      šŸ‘ļø0
      Mark102 Mark102 12 months ago
      Been Holding since 6. Buyout or partnership is imminent.
      šŸ‘ļø0
      1hot toddy 1hot toddy 12 months ago
      HUGE BUYS NOW 10K BUY $100K BUY $$$$$$$$$$$$$$$$$$
      šŸ‘ļø0
      Bud-Wiser Bud-Wiser 12 months ago
      Nice comeback today -Iā€™m back in
      šŸ‘ļø0
      1hot toddy 1hot toddy 12 months ago
      WOOOOOOOOOOOW 10K AND 9100 SHARE BUYS 2-$100,000 BUYS $$$$$$$$$$$$$$$$$$$$$$$$$$$$$
      BABY MONSTER HERE
      šŸ‘ļø0
      eyeownu eyeownu 12 months ago
      got dammmmmmmmmmm. oprah must be buying out the company
      šŸ‘ļø0
      1hot toddy 1hot toddy 12 months ago
      WOOOOOOW 10,000 SHARE BUY $110,000 BUY $$$$$$$$$$$$$$$$
      MONSTER WEIGHT LOSS CO HERE
      šŸ‘ļø0
      Mark102 Mark102 12 months ago
      Next Gap to 19 to fill. PT 60 to 100 on a buyout
      šŸ‘ļø0
      1hot toddy 1hot toddy 1 year ago
      WOOOOOOOOOOOW 21000 SHARE BUY OVER $150,000 BUY . KILLER WEIGHT LOSS HERE $$$$$$$$$$$
      šŸ‘ļø0
      eyeownu eyeownu 1 year ago
      rallys over IMO. end of year.. could be wrong tho!
      šŸ‘ļø0
      1hot toddy 1hot toddy 1 year ago
      WOOOOOOOOOOW 11000 SHARE BUY $90000 BUY WEIGHT LOSS RESULTS GREAT $$$$$
      šŸ‘ļø0

      Your Recent History

      NASDAQ
      ALT
      Altimmune
      BIT
      SGF
      Sogefi
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads